The body as a manufacturer of endostatin

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Antiangiogenesis gene therapy using endostatin has been surrounded by considerable controversy in the headlines of US national newspapers.

References

  1. 1

    O'Reilly, M.S. et al. Cell 79, 315–328 (1994).

  2. 2

    O'Reilly, M.S. et al. Cell 88, 277–285 (1997).

  3. 3

    Blezinger, P. et al. Nat. Biotechnol. 17, 343– 348 (1999).

  4. 4

    Augustin, H.G. Trends Pharmacol. Sci. 19, 216–22 (1998).

  5. 5

    Kong, H-L. & Crystal, R.G. J. Natl. Cancer Inst. 90, 273–286 (1998).

  6. 6

    Kolata, G. The New York Times May 5, p. 1 (1998).

  7. 7

    King, R.T. Jr. The Wall St. Journal November 1, pA1 (1998 ).

  8. 8

    Cohen,J. Science 283, 1250–1251 ( 1999).

  9. 9

    Folkman, J. Proc. Natl. Acad. Sci. USA 95, 9064– 9066 (1998).

  10. 10

    Crystal, R.G. Science 270, 404–410 ( 1995).

  11. 11

    Anderson, W.F. Nature 392 (suppl.), A25–A30 (1998).

  12. 12

    Ye, X. et al. Science 283, 88–91 ( 1999).

  13. 13

    Narumi, K. et al. Blood 92, 822–833 ( 1998).

  14. 14

    Suzuki, M. et al. Hum. Gene Ther 7, 1883–1893 (1996).

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Crystal, R. The body as a manufacturer of endostatin. Nat Biotechnol 17, 336–337 (1999). https://doi.org/10.1038/7890

Download citation

Further reading